-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GOkqkLpDKsbNqTYLw9IKjWZzb+oqzpu9t67Gv+Ante2NJ++DE3D7g36hSj/fRIwx
 A2pQpLwpN01N1pa/4zl7MQ==

<SEC-DOCUMENT>0001102624-07-000108.txt : 20070419
<SEC-HEADER>0001102624-07-000108.hdr.sgml : 20070419
<ACCEPTANCE-DATETIME>20070419170243
ACCESSION NUMBER:		0001102624-07-000108
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070419
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070419
DATE AS OF CHANGE:		20070419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		07776618

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: April     19, 2007</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On April 19, 2007 ImmuCell Corporation (the "Company") issued a press release announcing its financial results for the three month period ended March 31, 2007.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act ("the Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated April     19, 2007</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: April     19, 2007<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated April     19, 2007</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for First Quarter of 2007</b>
<p>PORTLAND, ME -- 04/19/2007 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three-month period ended
March 31, 2007.
</p>
<p>
For the three months ended March 31, 2007, product sales were $1,509,000,
representing an increase of $71,000, or 5%, in comparison to the same
period in 2006.  Net income per diluted share was $0.10 during the
three-month periods ended March 31, 2007 and 2006.  The Company recognized
net income of $297,000 during the three months ended March 31, 2007,
compared to net income of $306,000 during the same period in 2006.
</p>
<p>
"The product sales growth is attributable principally to an 8% increase in
sales of our lead product, First Defense&#174;," commented Michael F. Brigham,
President and CEO.  "We are nearing completion of an investment of
approximately $1,500,000 in Company-owned facility renovations and new
equipment.  This project is an integral part of our goal to become cGMP
compliant across all products.  We believe these increased standards will
bring added quality to our products and may open access to foreign markets
where cGMP is required."
</p>
<p>
Cash, cash equivalents and short-term investments decreased by 11%, or
$704,000, to $5,911,000 at March 31, 2007, as compared to $6,614,000 at
December 31, 2006.  As of March 31, 2007, the Company had paid
approximately $950,000 for equipment and facility improvements related to
an effort to gain compliance with current Good Manufacturing Practices
(cGMP) regulations in its manufacturing operations.  It is expected that
the remaining budget of approximately $550,000 will be spent as the work is
completed in the second quarter of 2007.  Shareholders' equity increased by
4%, or $332,000, to $9,664,000 at March 31, 2007, as compared to $9,332,000
at December 31, 2006.  The Company had 2,903,000 shares of common stock
outstanding as of March 31, 2007.
</p>
<p>
Forward-Looking Statement Disclaimer:  This press release contains
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934, including statements concerning possible future benefits of attaining
cGMP status and the future cost and timing of investments to attain cGMP
status.  These matters involve various risks and uncertainties, including
regulatory risks associated with obtaining cGMP compliance and market risks
associated with selling relevant ImmuCell products in domestic and foreign
markets.  Future Company performance is subject to various risk factors
discussed in more detail in the Company's latest Annual Report on Form
10-KSB.
<pre>
                                                          (Unaudited)
                                                          Three Months
                                                         Ended March 31,
                                                    -----------------------
(In thousands, except per share amounts)                2006        2007
                                                    ----------- -----------
Revenues:
Product sales                                       $     1,438 $     1,509
Other revenues                                              106         166
                                                    ----------- -----------
Total revenues                                            1,544       1,675

Cost and expenses:
Product costs                                               509         630
Product development expenses                                235         266
Selling, general and administrative expenses                343         348
                                                    ----------- -----------
Total costs and expenses                                  1,087       1,244
                                                    ----------- -----------

Net operating income                                        457         431

Interest and other income                                    52          77
                                                    ----------- -----------

Income before income taxes                                  509         508
Income tax expense                                          203         211
                                                    ----------- -----------
Net income                                          $       306 $       297
                                                    =========== ===========

Net income per common share:
Basic                                               $      0.11 $      0.10
Diluted                                             $      0.10 $      0.10

Weighted average common shares outstanding:
Basic                                                     2,852       2,897
Diluted                                                   3,058       3,063




                                                    ----------- -----------
                                                     At December  At March
(In thousands)                                        31, 2006    31, 2007
                                                    ----------- -----------
Cash, cash equivalents and short-term investments   $     6,614 $     5,911
Total assets                                             11,364      11,241
Net working capital                                       6,934       6,545
Stockholders&#146; equity                                $     9,332 $     9,664
</pre>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
